Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000516810 | SCV000614612 | benign | not specified | 2024-08-29 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000871807 | SCV001013530 | benign | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q; Epidermolysis bullosa simplex with nail dystrophy | 2024-12-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002255424 | SCV002526533 | likely benign | not provided | 2018-08-30 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Ambry Genetics | RCV002527511 | SCV003697105 | uncertain significance | Inborn genetic diseases | 2021-10-29 | criteria provided, single submitter | clinical testing | The c.2221A>G (p.I741V) alteration is located in exon 19 (coding exon 18) of the PLEC gene. This alteration results from a A to G substitution at nucleotide position 2221, causing the isoleucine (I) at amino acid position 741 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV002255424 | SCV004042353 | likely benign | not provided | 2023-10-01 | criteria provided, single submitter | clinical testing | PLEC: BP4, BS1 |